Today, the Trump Administration finalized improvements to Medicare Advantage and Medicare Part D, which provide seniors with medical and prescription drug coverage through competing private insurance plans.
Delay in Final Chimeric Antigen Receptor (CAR) T-cell therapy National Coverage Determination
From a CMS spokesperson:
The Centers for Medicare & Medicaid Services (CMS) issued a final rule on May 16, 2019 that modernizes and improves the Medicare Advantage and Part D programs. These changes will ensure that patients have greater transparency into the cost of prescription drugs in Part D and will also enable Medicare Advantage plans to negotiate better prices for physician-administered medicines in Part C.
Agency issues guidance for Medicaid Managed Care and CHIP health plans that clarifies how current regulations require “spread pricing” to be accounted in the calculation of Medical Loss Ratios (MLRs)
Remarks by Administrator Seema Verma at the National Rural Health Association Annual Conference (As prepared for delivery – May 8, 2019)
Remarks by Administrator Seema Verma at the Medical Device Manufacturers Association Annual Meeting (As prepared for delivery – May 2, 2019)
The Centers for Medicare & Medicaid Services (CMS) today released the Medicaid Provider Reassignment Regulation final rule removing a state’s ability to divert portions of Medicaid provider payments to third parties outside of the scope of what the statute allows.